Induction of Cell Death in U937 Myeloid Leukemia Cell Line Co-cultured with Genetically Engineered Adipose-derived Stem Cells Expressing a High Level of Bone Morphogenetic Protein 4 through miR-424-5p

Message:
Article Type:
Research/Original Article (دارای رتبه معتبر)
Abstract:
Introduction
Acute myeloid leukemia (AML) is a heterogeneous and complex malignancy characterized by rapid cellular proliferation, an aggressive clinical course, and generally high mortality. Transforming growth factor-beta (TGF-β) plays a significant role in tumorigenesis. Bone morphogenetic protein 4 (BMP4) is a member of the TGF-β superfamily whose expression is mainly controlled by the Smad signaling pathway. Studies have shown that this protein can control and induce the expression of some microRNAs during the cancer treatment process. MiR-424-5p plays an essential role in various types of cancer at different stages of tumorigenesis, including the promotion and/or inhibition of tumorigenesis, regulation of tumor development in the tumor microenvironment, and influencing cancer chemotherapy outcomes. The aim of this study was to evaluate the induction of cell death in the U937 myeloid leukemia cell line co-cultured with genetically engineered adipose-derived stem cells (ADSCs) expressing a high level of BMP4 through miR-424-5p.
Materials and Methods
The induction of cell death and apoptosis in the U937 cell line was assessed using MTT and Annexin V/ PI assays, respectively. The expression of miR-424 and TGF-β was determined in the co-culture system using real-time PCR.
Results
The results of MTT and Annexin V/ PI assays showed that BMP4-expressing adipose-derived stem cells (ADSCs) induced cell death in U937 cells in the co-culture system. Co-culture of engineered ADSCs with the U937 cell line led to the downregulation of miR-424 and TGF-β genes in U937 cells.
Conclusions
In the current study, a new strategy based on BMP4 induction was designed to significantly suppress the cell viability of the leukemia cell line U937. It appears that the use of engineered ADSCs could be useful for the treatment of hematological malignancies.
Language:
English
Published:
Journal of Applied Biotechnology Reports, Volume:10 Issue: 3, Summer 2023
Pages:
1109 to 1118
https://magiran.com/p2631965  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 1,390,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!